ACADIA Pharmaceuticals - ACAD Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $35.82
Forecasted Upside: 112.98%
Number of Analysts: 15
Breakdown:
0 Sell Ratings
3 Hold Ratings
12 Buy Ratings
0 Strong Buy Ratings

^$16.82 As of 04/19/2024 05:00 PM ET

▼ -0.25 (-1.46%)

1 month | 3 months | 12 months

Get New ACADIA Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ACAD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACAD

^$35.82

▲ +112.98% Upside Potential

This price target is based on 15 analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $35.82, with a high forecast of $95.00 and a low forecast of $25.00. The average price target represents a 112.98% upside from the last price of $16.82.

Current Consensus is Moderate Buy

The current consensus among 15 investment analysts is to moderate buy stock in ACADIA Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
12 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

10/27/2022

0 strong buy ratings
12 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

1/25/2023

0 strong buy ratings
12 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

4/25/2023

0 strong buy ratings
12 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

7/24/2023

0 strong buy ratings
12 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

10/22/2023

0 strong buy ratings
12 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

1/20/2024

0 strong buy ratings
12 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/20/2024

0 strong buy ratings
12 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

4/19/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/10/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$37.00	Low
4/9/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$32.00	Low
3/25/2024	JPMorgan Chase & Co.	Lower Target	Overweight ➝ Overweight	$29.00 ➝ $25.00	Low
3/13/2024	Morgan Stanley	Lower Target	Overweight ➝ Overweight	$40.00 ➝ $30.00	Low
3/12/2024	Needham & Company LLC	Lower Target	Buy	$36.00 ➝ $32.00	Low
3/12/2024	Mizuho	Downgrade	Buy ➝ Neutral	$39.00 ➝ $25.00	Low
3/1/2024	JPMorgan Chase & Co.	Lower Target	Overweight ➝ Overweight	$32.00 ➝ $29.00	Low
2/28/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$33.00	Low
2/28/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$42.00	Low
2/28/2024	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$36.00 ➝ $35.00	Low
2/28/2024	Mizuho	Lower Target	Buy ➝ Buy	$40.00 ➝ $39.00	Low
2/28/2024	Needham & Company LLC	Lower Target	Buy ➝ Buy	$37.00 ➝ $36.00	Low
2/7/2024	JMP Securities	Reiterated Rating	Market Outperform ➝ Market Outperform	$42.00	Low
2/5/2024	Oppenheimer	Reiterated Rating	Market Perform ➝ Market Perform	$25.00	Low
2/2/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$42.00	Low
1/30/2024	Robert W. Baird	Initiated Coverage	Outperform	$40.00	Low
1/24/2024	Needham & Company LLC	Upgrade	Hold ➝ Buy	$37.00	Low
12/29/2023	Mizuho	Boost Target	Buy ➝ Buy	$35.00 ➝ $40.00	Low
12/19/2023	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$31.00 ➝ $40.00	Low
12/18/2023	Stifel Nicolaus	Boost Target	Hold ➝ Hold	$25.00 ➝ $27.00	Low
12/14/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$42.00	Low
12/13/2023	Citigroup	Initiated Coverage	Buy	$38.00	Low
12/12/2023	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy ➝ Buy	$25.00	Low
11/6/2023	Mizuho	Upgrade	Neutral ➝ Buy	$20.00 ➝ $35.00	Low
11/3/2023	JMP Securities	Boost Target	Market Outperform ➝ Market Outperform	$39.00 ➝ $42.00	Low
11/3/2023	Royal Bank of Canada	Boost Target	Outperform ➝ Outperform	$32.00 ➝ $33.00	Low
11/3/2023	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $31.00	Low
10/17/2023	UBS Group	Initiated Coverage	Buy	$33.00	Low
10/10/2023	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$29.00 ➝ $32.00	Low
8/22/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$42.00	Low
8/7/2023	JPMorgan Chase & Co.	Boost Target	Neutral ➝ Neutral	$28.00 ➝ $29.00	Low
8/3/2023	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$30.00	Low
8/3/2023	Canaccord Genuity Group	Lower Target	Buy ➝ Buy	$39.00 ➝ $38.00	Low
8/3/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$33.00	Low
8/3/2023	Oppenheimer	Reiterated Rating	Market Perform ➝ Market Perform	$25.00	Low
7/28/2023	Oppenheimer	Boost Target		$23.00 ➝ $25.00	Low
7/17/2023	Cantor Fitzgerald	Boost Target		$36.00 ➝ $42.00	Low
7/17/2023	JPMorgan Chase & Co.	Boost Target		$21.00 ➝ $28.00	Low
7/14/2023	Citigroup	Boost Target	Neutral	$21.60 ➝ $27.00	Low
7/14/2023	Morgan Stanley	Boost Target	Equal Weight	$21.00 ➝ $30.00	Low
7/14/2023	Royal Bank of Canada	Boost Target	Outperform	$28.00 ➝ $33.00	Low
7/14/2023	HC Wainwright	Boost Target	Buy	$28.00 ➝ $33.00	Low
7/14/2023	Oppenheimer	Boost Target	Market Perform	$20.00 ➝ $23.00	Low
7/14/2023	JMP Securities	Boost Target	Market Outperform	$31.00 ➝ $39.00	Low
6/15/2023	Bank of America	Boost Target		$26.00 ➝ $29.00	Low
6/14/2023	JMP Securities	Boost Target	Market Outperform	$23.00 ➝ $31.00	Low
5/22/2023	Bank of America	Boost Target		$23.00 ➝ $26.00	Low
5/9/2023	JMP Securities	Boost Target	Outperform	$22.00 ➝ $23.00	Low
5/9/2023	Citigroup	Boost Target		$21.00 ➝ $21.60	Low
4/28/2023	Credit Suisse Group	Boost Target		$93.00 ➝ $95.00	Low
4/14/2023	Mizuho	Reiterated Rating	Neutral	$20.00	Low
3/14/2023	Canaccord Genuity Group	Boost Target	Buy	$24.00 ➝ $26.00	Low
3/14/2023	Royal Bank of Canada	Reiterated Rating	Outperform	$27.00	Low
3/14/2023	Morgan Stanley	Boost Target	Equal Weight	$19.00 ➝ $20.00	Low
3/14/2023	Guggenheim	Boost Target		$22.00 ➝ $25.00	Low
3/14/2023	Jefferies Financial Group	Boost Target		$10.00 ➝ $15.00	Low
3/14/2023	Mizuho	Boost Target		$19.00 ➝ $20.00	Low
3/14/2023	Cantor Fitzgerald	Boost Target	Overweight	$28.00 ➝ $33.00	Low
3/14/2023	Citigroup	Boost Target	Neutral	$19.40 ➝ $21.00	Low
3/14/2023	HC Wainwright	Boost Target	Buy	$25.00 ➝ $28.00	Low
3/13/2023	Mizuho	Reiterated Rating	Neutral	$19.00	Low
3/1/2023	Oppenheimer	Boost Target	Market Perform	$17.00 ➝ $20.00	Low
2/28/2023	Citigroup	Boost Target	Neutral	$19.00 ➝ $19.40	Low
2/28/2023	JMP Securities	Lower Target	Market Perform	$24.00 ➝ $22.00	Low
2/28/2023	HC Wainwright	Reiterated Rating	Buy	$25.00	Low
2/28/2023	Morgan Stanley	Boost Target	Equal Weight	$18.00 ➝ $19.00	Low
2/28/2023	Royal Bank of Canada	Boost Target	Outperform	$19.00 ➝ $27.00	Low
2/28/2023	Mizuho	Boost Target	Neutral	$15.00 ➝ $19.00	Low
2/15/2023	Oppenheimer	Boost Target	Market Perform	$16.00 ➝ $17.00	Low
1/31/2023	Citigroup	Boost Target	Neutral	$17.00 ➝ $19.00	Low
1/3/2023	Guggenheim	Upgrade	Neutral ➝ Buy	$22.00	Low
12/21/2022	Mizuho	Lower Target	Neutral	$17.00 ➝ $15.00	Low
11/14/2022	JPMorgan Chase & Co.	Lower Target	Overweight	$19.00 ➝ $17.00	Low
11/3/2022	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$15.00 ➝ $12.00	Low
11/3/2022	Royal Bank of Canada	Lower Target	Outperform	$22.00 ➝ $21.00	Low
11/1/2022	Loop Capital	Initiated Coverage	Hold	$17.00	Low
10/18/2022	HC Wainwright	Reiterated Rating	Buy	$25.00	Low
10/13/2022	Mizuho	Lower Target		$17.00	Low
10/7/2022	Mizuho	Lower Target		$19.00 ➝ $17.00	Low
8/9/2022	Morgan Stanley	Lower Target	Equal Weight	$22.00 ➝ $18.00	Low
8/9/2022	The Goldman Sachs Group	Lower Target	Neutral	$20.00 ➝ $15.00	Low
8/9/2022	Royal Bank of Canada	Lower Target	Outperform	$26.00 ➝ $21.00	Low
8/9/2022	Mizuho	Lower Target	Neutral	$27.00 ➝ $19.00	Low
8/9/2022	HC Wainwright	Boost Target	Buy	$20.00 ➝ $25.00	Low
8/9/2022	Citigroup	Boost Target		$15.00 ➝ $17.00	Low
8/9/2022	SVB Leerink	Lower Target	Outperform	$27.00 ➝ $21.00	Low
8/8/2022	Cowen	Lower Target	Outperform	$32.00 ➝ $21.00	Low
8/8/2022	Cowen	Lower Target	Outperform	$32.00 ➝ $21.00	Low
8/5/2022	Citigroup	Downgrade	Buy ➝ Neutral	$19.00 ➝ $15.00	Low
7/15/2022	Morgan Stanley	Lower Target	Equal Weight	$24.00 ➝ $22.00	Low
7/11/2022	SVB Leerink	Lower Target	Outperform	$31.00 ➝ $27.00	N/A
6/22/2022	Canaccord Genuity Group	Lower Target		$31.00 ➝ $20.00	Low
6/22/2022	Citigroup	Lower Target	Buy	$32.00 ➝ $19.00	Low
6/21/2022	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral		Low
6/21/2022	Jefferies Financial Group	Downgrade	Buy ➝ Underperform	$25.00 ➝ $10.00	Low
6/21/2022	Royal Bank of Canada	Lower Target	Outperform	$32.00 ➝ $26.00	Low
6/21/2022	Oppenheimer	Lower Target	Market Perform	$23.00 ➝ $19.00	Low
6/21/2022	Cantor Fitzgerald	Lower Target	Overweight	$37.00 ➝ $26.00	Low
6/21/2022	HC Wainwright	Lower Target	Buy	$36.00 ➝ $20.00	Low
6/16/2022	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$25.00	High
4/19/2022	Mizuho	Lower Target	Neutral	$28.00 ➝ $27.00	High
3/18/2022	Morgan Stanley	Reiterated Rating	Hold	$24.00	Medium
3/16/2022	Canaccord Genuity Group	Upgrade	Hold ➝ Buy	$30.00 ➝ $31.00	Low
3/10/2022	Cantor Fitzgerald	Boost Target	Overweight	$32.00 ➝ $37.00	High
3/7/2022	The Goldman Sachs Group	Lower Target	Neutral	$27.00 ➝ $24.00	Low
3/3/2022	Mizuho	Lower Target	Neutral	$33.00 ➝ $28.00	Low
3/1/2022	JMP Securities	Lower Target	Market Outperform	$42.00 ➝ $35.00	High
3/1/2022	Citigroup	Boost Target		$30.00 ➝ $32.00	High
2/9/2022	HC Wainwright	Upgrade	Neutral ➝ Buy	$18.00 ➝ $36.00	High
1/5/2022	Citigroup	Upgrade	Neutral ➝ Buy	$30.00	High
12/23/2021	SVB Leerink	Reiterated Rating	Buy		Low
12/21/2021	Bank of America	Boost Target	Neutral	$28.00 ➝ $32.00	Medium
12/21/2021	Citigroup	Boost Target	Neutral	$28.00 ➝ $30.00	High
12/21/2021	Royal Bank of Canada	Boost Target	Outperform	$32.00 ➝ $34.00	High
12/21/2021	JMP Securities	Boost Target	Market Outperform	$39.00 ➝ $42.00	High
12/21/2021	Guggenheim	Downgrade	Buy ➝ Neutral	$28.00	High
12/21/2021	Mizuho	Reiterated Rating	Hold		High
12/8/2021	The Goldman Sachs Group	Boost Target	Neutral	$25.00 ➝ $28.00	High
12/7/2021	Morgan Stanley	Boost Target	Equal Weight	$21.00 ➝ $24.00	High
12/7/2021	Oppenheimer	Boost Target	Market Perform	$20.00 ➝ $23.00	High
12/7/2021	JMP Securities	Boost Target	Outperform ➝ Market Outperform	$35.00 ➝ $39.00	High
12/7/2021	Cantor Fitzgerald	Boost Target	Positive ➝ Overweight	$27.00 ➝ $31.00	High
12/7/2021	Citigroup	Boost Target	Neutral	$25.00 ➝ $28.00	High
12/7/2021	Mizuho	Boost Target	Neutral	$24.00 ➝ $26.00	High
11/9/2021	Citigroup	Boost Target	Neutral	$22.00 ➝ $25.00	High
11/1/2021	Guggenheim	Upgrade	Neutral ➝ Buy	$19.00 ➝ $23.00	High
10/14/2021	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$17.00 ➝ $20.00	High
8/5/2021	Needham & Company LLC	Lower Target	Buy	$30.00 ➝ $26.00	High
8/5/2021	Morgan Stanley	Lower Target	Overweight	$29.00 ➝ $27.00	High
8/5/2021	SVB Leerink	Lower Target	Outperform	$31.00 ➝ $28.00	Medium
8/5/2021	Cantor Fitzgerald	Lower Target	Overweight	$33.00 ➝ $27.00	Medium
7/19/2021	SVB Leerink	Reiterated Rating	Outperform		High
7/10/2021	Raymond James	Set Target		$23.71	Low
7/9/2021	Raymond James	Reiterated Rating	Hold		Low
6/10/2021	Berenberg Bank	Initiated Coverage	Hold	$29.00	High
5/6/2021	Morgan Stanley	Boost Target	Overweight	$28.00 ➝ $29.00	High
5/6/2021	Mizuho	Reiterated Rating	Hold		High
4/13/2021	The Goldman Sachs Group	Reiterated Rating	Buy ➝ Neutral	$73.00 ➝ $25.00	Low
4/13/2021	Jefferies Financial Group	Reiterated Rating	Buy ➝ Hold	$40.00 ➝ $21.00	Low
4/13/2021	Mizuho	Reiterated Rating	Buy ➝ Neutral	$25.00	Low
4/13/2021	HC Wainwright	Reiterated Rating	Buy ➝ Neutral	$43.00 ➝ $18.00	N/A
4/7/2021	HC Wainwright	Downgrade	Buy ➝ Neutral	$43.00 ➝ $18.00	Medium
4/6/2021	SVB Leerink	Lower Target	Outperform	$63.00 ➝ $31.00	Low
4/6/2021	Morgan Stanley	Lower Target	Overweight	$50.00 ➝ $28.00	Low
4/6/2021	Cantor Fitzgerald	Boost Target	Overweight	$33.00 ➝ $45.00	Low
4/6/2021	Mizuho	Downgrade	Buy ➝ Neutral	$37.00 ➝ $25.00	Low
4/6/2021	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$40.00 ➝ $21.00	Low
4/5/2021	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$73.00 ➝ $25.00	High
4/5/2021	Raymond James	Downgrade	Outperform ➝ Market Perform		High
4/5/2021	Needham & Company LLC	Lower Target	Buy	$44.00 ➝ $30.00	High
3/16/2021	Bank of America	Reiterated Rating	Buy ➝ Neutral		High
3/15/2021	Stifel Nicolaus	Reiterated Rating	Buy ➝ Hold	$68.00 ➝ $27.00	N/A
3/15/2021	Raymond James	Reiterated Rating	Strong-Buy ➝ Outperform	$65.00 ➝ $35.00	N/A
3/15/2021	Guggenheim	Reiterated Rating	Buy ➝ Neutral		N/A
3/15/2021	Citigroup	Reiterated Rating	Buy ➝ Neutral	$66.00 ➝ $35.00	N/A
3/10/2021	Bank of America	Downgrade	Buy ➝ Neutral		High
3/9/2021	Guggenheim	Downgrade	Buy ➝ Neutral		High
3/9/2021	Morgan Stanley	Lower Target	Overweight	$65.00 ➝ $50.00	High
3/9/2021	Cowen	Lower Target	Outperform	$66.00 ➝ $57.00	High
3/9/2021	Oppenheimer	Lower Target	Market Perform	$42.00 ➝ $28.00	High
3/9/2021	Citigroup	Downgrade	Buy ➝ Neutral	$66.00 ➝ $35.00	High
3/9/2021	Needham & Company LLC	Lower Target	Buy	$60.00 ➝ $44.00	High
3/9/2021	Mizuho	Lower Target	Buy	$70.00 ➝ $55.00	High
3/9/2021	HC Wainwright	Lower Target	Buy	$60.00 ➝ $43.00	High
3/9/2021	Royal Bank of Canada	Lower Target	Outperform	$60.00 ➝ $36.00	High
3/9/2021	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$68.00 ➝ $27.00	High
3/9/2021	Raymond James	Downgrade	Strong-Buy ➝ Outperform	$65.00 ➝ $35.00	High
3/2/2021	Royal Bank of Canada	Boost Target	Outperform	$55.00 ➝ $63.00	High
2/25/2021	Morgan Stanley	Boost Target	Overweight	$60.00 ➝ $65.00	High
2/24/2021	Mizuho	Reiterated Rating	Buy	$69.00 ➝ $70.00	Medium
12/29/2020	Cantor Fitzgerald	Reiterated Rating	Overweight	$61.00 ➝ $70.00	N/A
12/16/2020	Morgan Stanley	Boost Target	Overweight	$58.00 ➝ $60.00	Low
12/15/2020	Mizuho	Initiated Coverage	Buy	$69.00	Medium
11/16/2020	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$65.00	High
11/5/2020	Morgan Stanley	Boost Target	Overweight	$57.00 ➝ $58.00	Medium
10/13/2020	Morgan Stanley	Boost Target	Overweight	$55.00 ➝ $57.00	Low
8/24/2020	Raymond James	Initiated Coverage	Outperform	$65.00	Low
8/20/2020	Morgan Stanley	Initiated Coverage	Overweight	$55.00	Medium
8/6/2020	HC Wainwright	Reiterated Rating	Buy		High
8/6/2020	Needham & Company LLC	Reiterated Rating	Buy	$60.00	Low
8/6/2020	SVB Leerink	Lower Target	Outperform	$56.00 ➝ $52.00	Medium
8/6/2020	Oppenheimer	Reiterated Rating	Hold	$42.00	Medium
7/21/2020	Jefferies Financial Group	Reiterated Rating	Buy	$60.00	High
7/21/2020	Citigroup	Lower Target		$69.00 ➝ $63.00	High
7/21/2020	Cantor Fitzgerald	Lower Target	Overweight	$63.00 ➝ $61.00	High
7/21/2020	Oppenheimer	Lower Target	Positive ➝ Market Perform	$53.00 ➝ $42.00	High
7/21/2020	Royal Bank of Canada	Lower Target	Outperform	$61.00 ➝ $55.00	High
7/16/2020	Needham & Company LLC	Initiated Coverage	Buy	$60.00	Low
7/9/2020	Royal Bank of Canada	Boost Target	Positive ➝ Outperform	$58.00 ➝ $61.00	Low
7/6/2020	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$41.00 ➝ $71.00	High
5/27/2020	Oppenheimer	Boost Target	Market Perform	$48.00 ➝ $53.00	Medium
5/8/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$50.00 ➝ $55.00	Medium
5/8/2020	Oppenheimer	Reiterated Rating	Hold	$48.00	High
5/8/2020	Cantor Fitzgerald	Boost Target	Buy	$58.00 ➝ $63.00	High
5/8/2020	Needham & Company LLC	Reiterated Rating	Buy		High
4/16/2020	Jefferies Financial Group	Initiated Coverage	Buy	$60.00	Low
3/31/2020	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$45.00 ➝ $72.00	High
3/5/2020	Citigroup	Initiated Coverage	Buy	$69.00	High
3/5/2020	Cowen	Reiterated Rating	Buy	$66.00	Medium
2/27/2020	HC Wainwright	Reiterated Rating	Buy	$60.00	High
2/27/2020	Cantor Fitzgerald	Reiterated Rating	Overweight	$70.00 ➝ $75.00	High
2/26/2020	JPMorgan Chase & Co.	Set Target	Outperform	$50.00	Medium
1/19/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
1/14/2020	Cowen	Reiterated Rating	Buy	$66.00	High
12/16/2019	Guggenheim	Initiated Coverage	Buy	$60.00	High
12/5/2019	HC Wainwright	Reiterated Rating	Buy	$60.00	High
12/5/2019	Cowen	Reiterated Rating	Buy	$66.00	High
11/27/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
11/26/2019	Cantor Fitzgerald	Boost Target	Overweight	$63.00 ➝ $70.00	Low
11/26/2019	Cowen	Initiated Coverage	Buy	$66.00	Low
11/26/2019	Royal Bank of Canada	Reiterated Rating	Buy	$60.00	Low
11/26/2019	HC Wainwright	Reiterated Rating	Buy	$60.00	Low
11/4/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$50.00	Low
11/1/2019	HC Wainwright	Reiterated Rating	Buy	$60.00	Medium
10/24/2019	Oppenheimer	Initiated Coverage	Market Perform	$44.00	Medium
10/1/2019	Royal Bank of Canada	Initiated Coverage	Outperform	$60.00	Low
9/23/2019	Cantor Fitzgerald	Boost Target	Overweight	$49.00 ➝ $56.00	Low
9/13/2019	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$21.00 ➝ $50.00	Low
9/10/2019	HC Wainwright	Set Target	Buy	$60.00	Medium
9/10/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		High
9/9/2019	Stifel Nicolaus	Set Target	Hold	$39.00	Medium
9/9/2019	Piper Sandler Companies	Boost Target	Overweight	$35.00 ➝ $56.00	High
9/9/2019	Cowen	Reiterated Rating	Buy	$66.00	Low
9/9/2019	Needham & Company LLC	Boost Target	Buy	$34.00 ➝ $60.00	High
9/3/2019	Stifel Nicolaus	Boost Target	Hold	$24.00 ➝ $28.00	High
8/27/2019	Cantor Fitzgerald	Reiterated Rating	Overweight	$30.00 ➝ $40.00	Low
8/5/2019	Needham & Company LLC	Reiterated Rating	Buy	$34.00	Low
8/1/2019	HC Wainwright	Reiterated Rating	Buy		Low
7/31/2019	JPMorgan Chase & Co.	Set Target	Buy	$32.00	N/A
7/31/2019	Bank of America	Set Target	Buy	$31.00	N/A
7/23/2019	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $34.00	High
7/1/2019	Needham & Company LLC	Reiterated Rating	Buy	$40.00	Low
5/31/2019	Raymond James	Boost Target	Strong-Buy	$40.00 ➝ $43.00	Low
5/3/2019	HC Wainwright	Reiterated Rating	Buy		High
5/2/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$31.00	High
4/25/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$30.00	Medium

(Data available from 4/19/2019 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

10 very positive mentions
6 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/22/2023

1 very positive mentions
4 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

10/22/2023

3 very positive mentions
8 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

11/21/2023

8 very positive mentions
24 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

12/21/2023

5 very positive mentions
4 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

1/20/2024

19 very positive mentions
19 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

2/19/2024

24 very positive mentions
36 positive mentions
10 negative mentions
4 very negative mentions

Mentions as of

3/20/2024

13 very positive mentions
17 positive mentions
10 negative mentions
0 very negative mentions

Mentions as of

4/19/2024

Current Sentiment

Recent Stories by Sentiment

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Today's Range

Now: $16.82

$16.62

$17.30

50 Day Range

MA: $21.03

$16.89

$26.76

52 Week Range

Now: $16.82

$16.60

$33.99

Volume

3,521,960 shs

Average Volume

1,783,722 shs

Market Capitalization

$2.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.37

Frequently Asked Questions

What sell-side analysts currently cover shares of ACADIA Pharmaceuticals?: The following equities research analysts have issued stock ratings on ACADIA Pharmaceuticals in the last year: Bank of America Co., Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, TheStreet, and UBS Group AG.
View the latest analyst ratings for ACAD.
What is the current price target for ACADIA Pharmaceuticals?: 17 Wall Street analysts have set twelve-month price targets for ACADIA Pharmaceuticals in the last year. Their average twelve-month price target is $35.82, suggesting a possible upside of 112.7%. Credit Suisse Group AG has the highest price target set, predicting ACAD will reach $95.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $25.00 for ACADIA Pharmaceuticals in the next year.
View the latest price targets for ACAD.
What is the current consensus analyst rating for ACADIA Pharmaceuticals?: ACADIA Pharmaceuticals currently has 3 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ACAD.
What other companies compete with ACADIA Pharmaceuticals?: Other companies that are similar to ACADIA Pharmaceuticals include MoonLake Immunotherapeutics, HUTCHMED, MorphoSys, Arrowhead Pharmaceuticals and Indivior. Learn More about companies similar to ACADIA Pharmaceuticals.
How do I contact ACADIA Pharmaceuticals' investor relations team?: ACADIA Pharmaceuticals' physical mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company's listed phone number is (858) 558-2871 and its investor relations email address is [email protected]. The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com. Learn More about contacing ACADIA Pharmaceuticals investor relations.

ACADIA Pharmaceuticals - ACAD Stock Price Target and Predictions

Analyst Price Target for ACAD

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.40 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of ACADIA Pharmaceuticals?

What is the current price target for ACADIA Pharmaceuticals?

What is the current consensus analyst rating for ACADIA Pharmaceuticals?

What other companies compete with ACADIA Pharmaceuticals?

How do I contact ACADIA Pharmaceuticals' investor relations team?